doxylamine succinate and pyridoxine hydrochloride

FDA Drug Profile — BONJESTA, Doxylamine Succinate and Pyridoxine Hydrochloride, DICLEGIS

Drug Details

Generic Name
doxylamine succinate and pyridoxine hydrochloride
Brand Names
BONJESTA, Doxylamine Succinate and Pyridoxine Hydrochloride, DICLEGIS
Application Number
NDA209661
Sponsor
Duchesnay USA, Inc.
NDC Codes
3
Dosage Forms
TABLET, EXTENDED RELEASE, TABLET, DELAYED RELEASE
Routes
ORAL
Active Ingredients
DOXYLAMINE SUCCINATE, PYRIDOXINE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Limitations of Use Doxylamine succinate and pyridoxine hydrochloride delayed-release tablet has not been studied in women with hyperemesis gravidarum. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are a fixed dose combination drug product of doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a Vitamin B6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. (1)